A Discussion of Silver as an Antimicrobial Agent: Alleviating the Confusion
- 1 Comments
- 19332 reads
Silver used as an antimicrobial agent has an impressive history. Silver (as well as copper) is used as a disinfectant in hospital and hotel water sanitization systems. It is used in the food industry in chicken farming and oyster cleaning to inhibit bacterial and fungal growth and in the space program to sterilize recycled water aboard the MIR space station and the NASA space shuttle.1 Although not employed in allopathic mainstream medicine, colloidal silver taken orally has been used as a complementary health aid, the overuse of which in some cases has lead to argyria (also referred to as “blue skin disease,” where the reduced silver is deposited in dermal cells. This explains how the term “blue blood” originated). Silver also is used as a preservative in cosmetics and toiletries and has been incorporated into plastics of various forms to protect against microbial contamination.
Silver has a long medicinal history, going as far back as ancient Greece and Rome, when silver coins dropped into water served as a disinfectant.2 As early as 1884, Crede, a German obstetrician, used a 1% silver nitrate solution to eliminate blindness in newborns caused by post-partum infection.3 In 1887, von Behring used the same compound to treat typhoid and anthrax. In 1964, Moyer4 first used silver in the burn arena; 4 years later, Fox5 brought silver sulfadiazine (SSD) to medicine. Silver-coated catheters have been used to stem biofilm formation and prevent infection.6
Over the last 3 to 5 years, an influx of “next generation” silver-based antimicrobial dressings has been introduced into the medical arena. A review of the literature, performed over the last 3 years using references going back 30+ years to the present (key words included resistance, strains, kill rate, dissociation, biofilm) along with time spent with clinicians, reveals specific areas of confusion with respect to silver as an antimicrobial agent — specifically, silver resistance, silver dissociation, silver concentration, strains of pathogens, rate of kill, and cytotoxicity of silver. These topics will be reviewed using available publications from the peer-reviewed literature, professional presentations, and independent data.
Although some authors downplay silver resistance, the majority of authors place a fair amount of emphasis on this issue.7-31 Ovington7 writes, “Although silver has been used effectively for centuries as an antimicrobial agent, we should not assume that bacterial resistance to silver will never become a problem. The genetic basis of bacterial resistance to silver has been identified in specific bacterial isolates and closely related gene sequences have been identified in other bacteria. With silver being used more extensively in both environmental and clinical applications — particularly in wound management — the threat of resistance is not unlikely and urges for prudent use of topical antimicrobial products of any type.” In another paper, Ovington32 theorizes that resistance to silver (an antiseptic) is possible, but is less common than resistance to antibacterial agents.
Based on their own and additional research,8,9,11,12,15,17,19,21,23-26,29,33 Gupta and Silver,8 in a literature review/commentary, both state that “silver resistance is important to monitor, because modern technology has developed a wide range of products that depend on silver as a key microcidal component.” According to Levy,9 “the widespread use of silver could result in more bacteria developing resistance, analogous to the emergence of antibiotic- and biocide-resistant bacteria.”
1. Searle A. The Use of Metal Colloids in Health & Disease. New York, NY: EP Sutton;1919:75.
2. American Medical Association Advisory Panel (eds). New and Unofficial Remedies. Philadelphia, Pa: Lippincott Publications;1950:100.
3. Goodman L, Gelman A. The Pharmacological Basis of Therapeutics. 5th Ed. New York, NY: MacMillian;1975:930.
4. Moyer CA, Brentono L, Gravens DL, Margrat HW, Monafo WW. Treatment of large human burns with 0.5% silver nitrate solution. Arch Surg. 1965;90:812.
5. Fox CL, Rappole BW, Stanford W. Control of Pseudomonas in burns with silver sulfadiazine. Surg Gynecol Obstet. 1969;(14):168.
6. Thibon P, Le Coutour X, Leroyer R, Fabry J. Randomized multi-centre trial of the effects of a catheter coated with hydrogel and silver salts on the incidence of hospital-acquired urinary tract infections. J Hosp Infect. 2000;45(2):117–124.
7. Ovington LG. The value of silver in wound management. Podiatry Today. 1999;12:59–62.
8. Gupta A, Silver S. Silver as a biocide: will resistance become a problem? Nature Biotechnology. 1998;16:888.
9. Levy SB. The challenge of antibiotic resistance. Scientific American. 1998;3:32–39.
10. Slawson RM, VanDyke MI, Trevors JT. Germanium and silver resistance, accumulation and toxicity in microorganisms. Plasmid. 1992;27:72–79.
11. Li X-Z, Nikaido H, Williams KE. Silver-resistant mutants of Escherichia coli display active efflux of Ag+ and are deficient in porins. J Bacteriol. 1997;179(19):6127–6132.
12. Gupta A, Matsui K, Lo F, Silver S. Molecular basis for resistance of silver cations in Salmonella. Nature Medicine. 1999; 5(2):183–188.
13. Gupta A, Maynes M, Silver S. Effects of halides on plasmid-mediated silver resistance in Escherichia coli. Appl Env Microbiol. 1998;12:5042–5045.
14. Clement JL, Jarrett PS. Antibacterial silver. Metal-Based Drugs. 1994;1(5-6):1467–1482.
15. Deshpande LM, Chopade RA. Plasmid mediated silver resistance in Acinetobacter baumannii. Biometal. 1994;7:49–56.
16. Goddard J, Bull TA. The isolation and characterization of bacteria capable of accumulating silver. Appl Microbiol Biotechnol. 1989;31:308–313.
17. McHugh SL, Moellering CC, Hopkins CC, Swartz MN. Salmonella typhimurium resistant to silver nitrate, chloramphenicol and ampicillin. Lancet. 1975;1:235–240.
18. Starodub ME, Trevors JT. Mobilization of Escherichia coli R1 silver-resistance plasmid pJT1 by Tn5-mob into Escherichia coli C600. Biol Metals. 1990;3:24–27.
19. Slawson RM, Trevors JT, Lee H. Silver accumulation and resistance in Pseudomonas stutzeri. Arch Microbiol. 1992;158:398–404.
20. Gadd GM, Laurence OS, Briscoe PA, Trevors JT. Silver accumulation in Pseudomonas stutzeri AG259. Biol Metals. 1989;2:168–173.
21. Haefeli C, Franklin C, Hardy K. Plasmid-determined silver resistance in Pseudomonas stutzeri isolated from a silver mine. J Bacteriol. 1984;158:389–392.
22. McFaddin JF. Biochemical Tests for Identification of Medical Bacteria. Baltimore, Md; The Williams and Wilkins Company;1976:89–99.
23. Hendry AT, Stewart IO. Silver-resistant Enterobacteriaceae from hospital patients. Can J Microbiol. 1979;25:915–921.
24. Modak SM, Fox CR Jr. Sulfadiazine silver-resistant Pseudomonas in burns. Arch Surg. 1981;116:854–857.
25. Silver S, Phung LT. Bacterial heavy metal resistance mechanism: new surprises. Ann Rev Microbiol. 1996;50:753–789.
26. Starodub ME, Trevors JT. Silver resistance in Escherichia coli R1. J Med Microbiol. 1989;29:101–110.
27. Silver S, Ji G. Newer systems for bacterial resistance to toxic heavy metals. Environ Health Perspect. 1994;102suppl3:107–113.
28. Cervantes C, Silver S. Metal resistance in Pseudomonas: genes and mechanisms. In: Nakazawa T, Furukawa K, Silver S. Molecular Biology of Pseudomonads. Washington, DC: American Society for Microbiology; 1996:398.
29. Solioz M, Odermatt A. Copper and silver transport by CopB-ATPase in membrane vesicles of Enterococcus hirae. J Biol Com. 1995; 270:9217–9221.
30. Starodub ME, Silver JT. Silver accumulation and resistance in Escherichia coli R1. J Inorg Biochem. 1990;39:317–325.
31. Nikaido H. Prevention of drug access to bacterial targets: role of permeability barrier and active efflux. Science. 1994;264:382–388.
32. Ovington LG. The truth about silver. Ostomy Wound Manage. 2004;50(9A suppl):1S–10S..
33. Li X-Z, Nikaido H, Poole K. Role of MexA-MexB-OprM in antibiotic efflux in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1995;39:1948–1953.
34. Parsons D. Bowler PG, Walker M. Letter to the editor: polishing the information on silver. Ostomy Wound Manage. 2003;49(8):10–18.
35. Bowler P. Conference Presentation Sponsored by Convatec Australia. New Zealand Burn Association Meeting (ANZBA), October 21-24, 2002, Auckland, New Zealand.
36. Zhao Z, Cornell K, Hopman L, Gibbins B. SilvaSorb targeted antimicrobial activity: a technical document explaining the methodology and benefits of a targeted release of antimicrobial silver. Available at: http://www.acrymed.com/Aug2002/SilvaSorbTargetedActivity.html Accessed January 25, 2005.
37. Schierholz JM, Wachol-Drewe Z, Lucas LJ, Pulvere G. Activity of silver in different media. Zentralblatt fur Bakteriologie. 1998;287:411–420.
38. Ovington LG. The role of silver technology in wound healing, part 2: why is nanocrystalline silver superior? WOUNDS. 2001;13(supplB2):5–10
39. Parsons D, Bowler PG, Myles V, Jones S. Silver antimicrobial dressings in wound management: a comparison of antibacterial, physical and chemical characteristics, WOUNDS. 2005;17(8):222–232.
40. Wright JB, Hansen L, Burrell RE. The comparative efficacy of two antimicrobial barrier dressings: in-vitro examination of two controlled-release silver dressings. WOUNDS. 1998;10(6):179–188.
41. Zumdahl SS. Chemistry, 1st edition. Lexington, Mass: DC Heath and Company; 1986,:547–548.
42. Sikka R, Sabherwal U, Arora DR. Susceptibility of Klebsiella pneumoniae to heavy metal ions in vitro. Indian J Med. 1987;Res 86(Oct.):437–440.
43. Findik D, Tuncer I, Mahmuriye M, Atademir S. Nosocomial fungal infections in a teaching hospital in Turkey: identification of the pathogens and their antifungal susceptibility patterns. Turkish Journal of Medical Sciences. 2002;32(1):35–38.
44. Boyce ST, Warden GD, Holder IA. Nontoxic combinations of topical antimicrobial agents for use with cultured skin substitutes. Antimicrob Agents Chemother. 1995;39(6):1324–1328.
45. Maple PA, Hamilton-Miller JMT, Brumfitt W. Comparison of the in-vitro activities of the topical antimicrobials azelaic acid, nitrofurazone, SSD and mupirocin against MRSA. J Antimicrob Chemother. 1992;29:661–668.
46. Spadaro JA, Berger TJ, Barranco SD, Chapin SE, Becker RO. Antibacterial effects of silver electrodes with weak direct current. Antimicrobial Agents Chemother. 1974;6(5):637–642.
47. Marino AA, Deitch EA, Malakano, V, Albright JA, Specian RD. Electrical augmentation of the antimicrobial activity of silver-nylon fabrics. J Biolog Physics. 1984;12:93–98.
48. Deitch EA, Marino AA, Malakanok V, Albright JA. Silver nylon cloth: in vitro and in vivo evaluation of antimicrobial activity. J Trauma. 1987;27(3):301–304.
49. Hall RE, Bender G, Marquis RE. Inhibitory and cidal antimicrobial actions of electrically generated silver ions. J. Oral Maxillofac Surg. 1987;45:779–784.
50. Yin HQ, Langford R, Burrell RE. Comparative evaluation of the antimicrobial activity of Acticoat antimicrobial barrier dressing. J Burn Care Rehabil. 1999;20:195–200.
51. Spacciapoli P, Buxton D, Rothstein D, Friden P. Antimicrobial activity of silver nitrate against periodontal pathogens. J Periodont Res. 2001;36:108–113.
52. Vanscheidt W, Lazareth I, Routkovsky-Norval C. Safety evaluation of a new ionic silver dressing in the management of chronic ulcers. WOUNDS. 2003;15(11):371–378.
53. Ricketts CR, Lowbury EJ, Lawrence JC, Hall M, Wilkins MD. Mechanism of prophylaxis by silver compounds against infection of burns. Br Med J. 1970;2:444–446.
54. Carr HS, Wlodkowski TJ, Rosenkranz HS. Silver sulfadiazine: in vitro antibacterial activity. Antimicrob Agents Chemother. 1973;4(6):585–587.
55. Stratton CW, Cooksey RC. Susceptibility tests: special tests. In: Ballows R, Hausler WJ, et al. Manual of Clinical Microbiology, 5th ed. Washington DC: ASM International;1991:1153–1165.
56. Caddow P. Microorganisms and their properties. In: Applied Microbiology 1st ed. London, England: Scutari Press;1989:17–42.
57. Lowbury EL. Problems of resistance in open wounds and burns. In: Mouton RP, Brumfitt W, Hamilton-Miller JMT (eds.). The Rational Choice of Antibacterial Agents. The Netherlands: Kluwer Harrap Handbook;1977.
58. Harrison-Balestra C, Cazzaniga AL, Davis SC, et al. A wound-isolated Pseudomonas aeruginosa grows a biofilm in vitro within 10 hours and is visualized by light microscopy. Dermatolog Surg. 2003;29(6):631.
59. Tredget EE, Shankowsky H, Groeneveld A, Burrell R. A matched-pair, randomized study evaluating the efficacy and safety of Acticoat silver-coated dressing for the treatment of burn wounds. J Burn Care Rehabil. 1998;19(6):531–537.
60. Poon KM, Burd A. In vitro toxicity of silver: implication for clinical wound care. Burns. 2004;30:140–147.
61. Lam PK, Chan ESY, Ho WS, Liew CT. In vitro cytotoxicity testing of nanocrystalline silver dressing (Acticoat) on cultured keratinocytes. Brit J Biomed. 2004;61(3):125–127.
62. Innes ME, Umraw N, Fish JS, Gomez M, Cartotto RC. The use of silver-coated dressings on donor site wounds: a prospective, controlled matched pair study. Burns. 2001;6:621–627.
63. Honari S, Gibran NS, Engrav LH, Carlson AR, Heimbach DM. Clinical benefits and cost effectiveness of Acticoat for donor sites. Burn Care & Rehabil. 2001;3:74–78.
64. Perlov CD, Barton R, Corley R, Shack RB. Managing difficult donor sites with silver-impregnated dressings. Poster presentation at the Symposium on Advanced Wound Care. Las Vegas, Nev. April 30–May 3, 2001.
65. Hanna MK, Slugocki GMJ, Hickerson WL. A prospective study comparing the efficacy and patients satisfaction of Xeroform gauze dressings versus Acticoat silver-coated dressings for the treatment of skin graft donor sites. Abstract Presented at John A. Boswick, M.D. Burn and Wound Care Symposium. Maui, Hawaii. February 2001.
66. Strohal R, Schelling M, Takacs M, Jurecka W, Gruber U, Offner F. Nanocrystalline silver dressings as an efficient anti-MRSA barrier: a new solution to an increasing problem. Oral presentation, Second World Union of Wound Healing Societies Meeting. Paris, France. July, 2004.
67. Voigt DW, Paul CN. The use of Acticoat and silver-impregnated Telfa dressings in a regional burn and wound care center: the clinicians view. WOUNDS. 2001;13(supplB2):11–20.
68. Demling RH, De Santi L. The rate of re-epithelialization across meshed skin grafts is increased with exposure to silver. Burns. 2002;28:264–266.
69. Dunn K, Edwards-Jones V. The role of Acticoat with nanocrystalline silver in the management of burns. Burns. 2004;(1suppl30):S1–S9.
70. Yin HQ, Langford R, Tredget EE, Burrell RE. Effect of Acticoat antimicrobial barrier dressing on wound healing and graft take. J Burn Care Rehabil. 1999;Jan/Feb:S231.
71. DeLang BG, Sutherland JM, Peace LVN. Combination therapy using human fibroblast-derived dermal substitute and silver-impregnated dressing for chronic infected lower extremity diabetic ulcers. Poster presentation. Department of General Vascular Surgery, University of North Texas Health Science Center, Ft. Worth, Tex;2002.
72. Sibbald RG. A single centre, open-label pilot study to determine the effects of application of Acticoat™ 7 antimicrobial barrier dressing in the treatment of chronic venous leg ulcers. Oral presentation. Second World Union of Wound Healing Societies’ Meeting. Paris, France. July 2004.
73. Sibbald RG, Brown AC, Coutts P, Queen D. Screening evaluation of an ionized nanocrystalline silver dressing in chronic wound care. Ostomy Wound Manage. 2001;47(10):38–43.